Comparing the Efficacy of Intravitreal Dexamethasone and Time-displaced Fluocinolone Acetonide on Central Retinal Thickness in Patients with Uveitis

Ocul Immunol Inflamm. 2023 Jan;31(1):168-174. doi: 10.1080/09273948.2021.2018469. Epub 2022 Jan 26.

Abstract

Background: To compare the efficacy of intravitreally administered dexamethasone (Dex) and subsequent time-displaced fluocinolone acetonide (FA) on central subfield thickness (CST) in eyes with noninfectious uveitis.

Methods: Retrospective analysis of twenty-three eyes (18 patients) subsequently receiving intravitreal Dex and FA implants. The main outcome measures were CST, best-corrected visual acuity (BCVA), intraocular pressure (IOP), and status of inflammation.

Results: CST (Dex: p < .0001; FA: p = .0008) and BCVA (Dex: p = .0009; FA: p = .0005) improved significantly with both implants. Significantly better effects were noted with Dex for absolute and relative CST reduction (p = .0089 and p = .0051, respectively). Final BCVA did not differ between groups (p = .1893). Dex significantly increased IOP, whereas FA did not. One eye was actively inflamed after Dex and FA injection at follow-up (inflamed eyes before injection: [Dex: 2; FA: 6]).

Conclusion: Both implants significantly reduced CST and induced a significant gain in visual acuity. Dex might be more effective in reducing CST.

Keywords: Central retinal thickness; dexamethasone; fluocinolone; intravitreal steroids; non-infectious uveitis.

MeSH terms

  • Dexamethasone
  • Drug Implants
  • Fluocinolone Acetonide*
  • Follow-Up Studies
  • Glucocorticoids / therapeutic use
  • Humans
  • Intravitreal Injections
  • Retrospective Studies
  • Treatment Outcome
  • Uveitis* / diagnosis
  • Uveitis* / drug therapy

Substances

  • Fluocinolone Acetonide
  • Glucocorticoids
  • Dexamethasone
  • Drug Implants